SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Decision Diagnostics Corp. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
The Californer/10114957

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Decision Diagnostics Corp. ("Decision Diagnostics" or "the Company") (OTC: DECN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 3, 2020 and December 17, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before March 16, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

More on The Californer

• Attn: Newspaper Publishers, Editors & Sales: Looking for ways to Beat the Print Apocalypse…Again?
• 2026 Black History Month Film Screenings by 100 Films Retreat #12 in Solamonte Glass Booth
• California Book Publishers Turns Author Visions into Professional Publications
• Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
• California: Governor Newsom announces the commitment of over 160 lenders to extend mortgage relief for LA fire survivors

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Decision Diagnostics failed to develop a viable COVID-19 test in any form, let alone a test that could detect the virus in less than one minute. The Company was not capable of meeting the FDA's EUA testing requirements for its purported COVID-19 test. Despite this inability to meet FDA requirements, the Company touted an unrealistic time to market for its tests. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Decision Diagnostics, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

---

Show All News | Report Violation